Purdue Sues TWi Over Insomnia Drug Generic Plans

Law360, New York (August 22, 2013, 4:08 PM ET) -- Purdue Pharma LP on Tuesday sued rival TWi Pharmaceuticals Inc. in New Jersey federal court, claiming a planned generic version of insomnia treatment Intermezzo infringed a pair of patents for the drug licensed to Purdue.

According to Purdue, Taiwanese drugmaker TWi’s planned 1.75- and 3.5-milligram dose sublingual tablet versions of zolpidem tartrate infringe on two patents — U.S. Patent Numbers 8,242,131 and 8,252,809 — covering Intermezzo, exclusively licensed to Purdue by drug development company Transcept Pharmaceuticals Inc.

“Plaintiffs will be irreparably harmed if TWi is not...
To view the full article, register now.